Date:10/13/2010

""; BitlyCB.alertResponse = function(data) { var s = ''; var first_result; // Results are keyed by longUrl, so we need to grab the first one. for (var r in data.results) { first_result = data.results[r]; break; } for (var key in first_result) { //s += key + ":" + first_result[key].toString() + "
"; if(key == "shortUrl") { shortURL = first_result[key].toString(); break; } } PostTwitter(); } function readCookie(name){ var cookieValue = ""; var search = name + "="; if(document.cookie.length > 0){ offset = document.cookie.indexOf(search); if (offset != -1){ offset += search.length; end = document.cookie.indexOf(";", offset); if (end == -1) end = document.cookie.length; cookieValue = unescape(document.cookie.substring(offset, end)) } } return cookieValue; } window.onload=function(){ OnNewsreleaseLoad(); var userid = readCookie('DMUserTrack'); var csid = 104860859; var newstogramURL = 'http://www.prnewswire.com/templates/PRN_MultiVu_URL_Reader?userid='+userid+'&csid='+csid; //var newstogramURL ='http://www.prnewswire.com/templates/prnwConfig.xml'; var delay = function() { sendToFlash('StartPlay',newstogramURL); }; setTimeout(delay,100,"JavaScript"); //setTimeout("sendToFlash('StartPlay', 'http://www.prnewswire.com/templates/prnwConfig.xml')",100); }; function ShortenURL() { //Bit.ly function call to shorten url BitlyClient.call('shorten', {'longUrl': formatURL()}, 'BitlyCB.alertResponse'); }

'/>"/>

SOURCE Elsevier Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9
Related biology technology :

1. Helix BioPharma Completes Definitive GLP Toxicology Studies With L-DOS47 and is Making Final Preparations for its Planned Phase I/II Clinical Study IND/CTA Submissions
2. Genesis Biopharma to Present at the Informed Investors Forum Biotech, Healthcare & Pharma Virtual Conference on October 13
3. PDL BioPharma Completes October 1 Special Dividend Payment
4. Genesis Biopharma Announces $700K Private Financing
5. Signal Genetics Announces Partnership with Array BioPharma to Advance a Multiple Myeloma Program Backed by Companion Diagnostics
6. Keryx Biopharmaceuticals to Present at the UBS 2010 Global Life Sciences Conference
7. Helix BioPharma Approved for NYSE Amex Listing
8. PDL BioPharma Provides Clarification Regarding Redemption of Its 2.75% Convertible Subordinated Notes
9. PDL BioPharma Provides Third Quarter 2010 Revenue Guidance of Approximately $86 Million and Update to its Correspondence With Genentech
10. Reportlinker Adds Advances in Biopharmaceutical Technology in China
11. PDL BioPharma Announces Retirement of $61.6 Million of 2.75% Convertible Notes due August 2023 for Common Stock